About MiNA Therapeutics
MiNA Therapeutics is a company based in London (United Kingdom) founded in 2008 by Pal Saetrom, Nagy Habib, and John Rossi.. MiNA Therapeutics has raised $458.78 million across 7 funding rounds from investors including Lilly, Boehringer Ingelheim and Nxera Pharma. The company has 37 employees as of December 31, 2022. MiNA Therapeutics offers products and services including RNAa Therapeutics and Pipeline Programs. MiNA Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 37 as on 31 Dec, 2022
- Founders Pal Saetrom, Nagy Habib, John Rossi
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mina Therapeutics Limited
- Date of Incorporation 07 Mar, 2008
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
$23.07 M (USD)839as on Dec 31, 2021
-
Net Profit
$-26.96 M (USD)-4681as on Dec 31, 2022
-
EBITDA
$-31.28 M (USD)-5520as on Dec 31, 2022
-
Total Equity Funding
$458.78 M (USD)
in 7 rounds
-
Latest Funding Round
$15 M (USD), Series A
Jul 06, 2021
-
Investors
Lilly
& 3 more
-
Employee Count
37
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MiNA Therapeutics
MiNA Therapeutics offers a comprehensive portfolio of products and services, including RNAa Therapeutics and Pipeline Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medicines that activate genes to restore cellular functions for disease treatment.
Advancing medicines for genetic diseases through research and trials.
Unlock access to complete
Unlock access to complete
Funding Insights of MiNA Therapeutics
MiNA Therapeutics has successfully raised a total of $458.78M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series A — $15.0M
-
First Round
First Round
(17 Dec 2014)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series A - MiNA Therapeutics | Valuation |
investors |
|
| Sep, 2020 | Amount | Series A - MiNA Therapeutics | Valuation | aMoon |
|
| May, 2019 | Amount | Series A - MiNA Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MiNA Therapeutics
MiNA Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Boehringer Ingelheim and Nxera Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in healthcare are focused on by aMoon.
|
Founded Year | Domain | Location | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Founded Year | Domain | Location | |
|
Generic drugs and clinical research services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MiNA Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MiNA Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mina Therapeutics Comparisons
Competitors of MiNA Therapeutics
MiNA Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mina Therapeutics
Frequently Asked Questions about MiNA Therapeutics
When was MiNA Therapeutics founded?
MiNA Therapeutics was founded in 2008 and raised its 1st funding round 6 years after it was founded.
Where is MiNA Therapeutics located?
MiNA Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of MiNA Therapeutics?
Robert Sebastian Habib is the current CEO of MiNA Therapeutics.
Is MiNA Therapeutics a funded company?
MiNA Therapeutics is a funded company, having raised a total of $458.78M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3.5M, raised on Dec 17, 2014.
How many employees does MiNA Therapeutics have?
As of Dec 31, 2022, the latest employee count at MiNA Therapeutics is 37.
What is the annual revenue of MiNA Therapeutics?
Annual revenue of MiNA Therapeutics is $23.07M as on Dec 31, 2021.
What does MiNA Therapeutics do?
Developer of small activating RNA therapeutics. It develops a new class of medicines that restore or boost normal gene function, impacting protein-modulated pathways in cells. The company focuses on genetic medicine applications and collaborates with pharmaceutical companies to expand its technology platform into other therapeutic areas. A systematic approach allows for rapid development of new medicines, moving from concept to clinical trials within a short timeframe. One RNA medicine has completed clinical trials.
Who are the top competitors of MiNA Therapeutics?
MiNA Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does MiNA Therapeutics offer?
MiNA Therapeutics offers RNAa Therapeutics and Pipeline Programs.
Who are MiNA Therapeutics's investors?
MiNA Therapeutics has 4 investors. Key investors include Lilly, Boehringer Ingelheim, Nxera Pharma, and aMoon.